NCT02141347 2018-12-12Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ MesotheliomaAstraZenecaPhase 1 Completed65 enrolled